Overview of Biologics Targeting Type 2 Inflammation in Respiratory Disease

Area of Science:

• Pulmonology
• Immunology
• Pharmacology

Background:

• Type 2 targeting biologics have revolutionized respiratory disease management, improving patient outcomes and reducing reliance on systemic corticosteroids.
• Approved biologics like benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, and tezepelumab are used for severe asthma and other airway diseases.

Purpose of the Study:

• To offer practical, evidence-based recommendations for selecting appropriate type 2 biologics across various respiratory conditions.
• To guide clinicians in choosing the most effective biologic therapy when multiple options are available.

Main Methods:

• Review of current literature and FDA-approved type 2 targeting biologics for respiratory diseases.
• Analysis of clinical factors influencing biologic selection, including diagnosis, prior treatment response, and inflammation type.

Main Results:

• Multiple biologics are approved for severe asthma, COPD, eosinophilic granulomatosis with polyangiitis, and chronic rhinosinusitis with nasal polyposis.
• Biologic selection requires confirming diagnosis, assessing treatment responsiveness, identifying type 2 inflammation, and considering patient-specific factors.

Conclusions:

• Selecting the optimal type 2 biologic requires a comprehensive approach, balancing clinical efficacy with practical considerations.
• Personalized medicine strategies are crucial for maximizing the benefits of biologic therapies in respiratory diseases.